Stoke Therapeutics (NASDAQ:STOK) had its price target dropped by equities research analysts at JPMorgan Chase & Co. from $34.00 to $33.00 in a research report issued to clients and investors on Tuesday, BenzingaRatingsTable reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 28.96% from the company’s current price.
A number of other equities analysts have also recently commented on STOK. Zacks Investment Research raised Stoke Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a report on Wednesday, October 16th. Cowen reaffirmed a “buy” rating on shares of Stoke Therapeutics in a research note on Thursday, August 15th. HC Wainwright started coverage on Stoke Therapeutics in a research report on Friday, October 25th. They set a “buy” rating and a $30.00 price target for the company. Finally, BTIG Research began coverage on Stoke Therapeutics in a research note on Tuesday, November 12th. They issued a “buy” rating and a $46.00 price objective for the company. Seven analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $35.17.
STOK opened at $25.59 on Tuesday. The firm’s fifty day moving average is $25.03. Stoke Therapeutics has a 52-week low of $19.21 and a 52-week high of $39.04.
Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 12th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. As a group, equities research analysts predict that Stoke Therapeutics will post -2.09 EPS for the current year.
In other Stoke Therapeutics news, major shareholder Rtw Investments, Lp sold 16,434 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $28.70, for a total value of $471,655.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders have purchased 205,216 shares of company stock valued at $5,771,421.
Several institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC purchased a new position in shares of Stoke Therapeutics during the 2nd quarter worth $11,668,000. Vanguard Group Inc. acquired a new position in shares of Stoke Therapeutics during the second quarter worth about $2,917,000. Ladenburg Thalmann Financial Services Inc. purchased a new stake in shares of Stoke Therapeutics during the second quarter worth approximately $88,000. Orbimed Advisors LLC purchased a new stake in shares of Stoke Therapeutics during the second quarter worth approximately $3,792,000. Finally, KCL Capital L.P. acquired a new stake in Stoke Therapeutics in the second quarter valued at approximately $292,000. 48.61% of the stock is owned by institutional investors and hedge funds.
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.
Read More: What is the Quick Ratio?
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.